Medical News
Early Access to Antiretroviral Therapy versus Standard of Ca...
J INT AIDS SOC
The observed improvement in retention in care and on the combined retention and viral suppression provides an...
21 Sep 2020
Association Between CD4 Count and Chemoradiation Therapy Out...
JAIDS
Higher delta CD4 (greater improvement from nadir CD4 to CD4 at cervical cancer diagnosis) is significantly...
18 Sep 2020
Association Between Atazanavir‐Induced Hyperbilirubinemia an...
JAHA
Patients with HIV on atazanavir manifest a decreased risk of cardiovascular disease when compared with those on...
16 Sep 2020
HIV-associated Plasmablastic Lymphoma in the Era of HAART: A...
AIDS
PBL is the second most common type of aggressive lymphoma and often presents in lymph nodes of patients with poorly...
07 Sep 2020
eCMEs
Key Trials
PRADAR Study: Virological Efficacy of Abacavir/Lamivudine + DRV/r vs Abacavir/ Lamivudine + RAL in Treatment -naïve HIV Patients with CD4<200 cells/μL
The present prospective, multicenter, randomized open-label, 2-arm, phase-3 trial compares the 48-week virological efficacy of two drug regimens...
Switching to FTC/TAF from FTC/TDF in Virologically Suppressed Patients receiving a Boosted PI or an Unboosted Third Agent
This is a 48-week subgroup analysis of evaluating the efficacy and safety of FTC/ TAF by the class of coadministered third agent (boosted PI vs...
ADVANCE Trial: DTG Combined with TAF or TDF, Noninferior to the Standard -of- care Regimen at Week 48
The ADVANCE trial compared the efficacy and safety of a triple-therapy combination of emtricitabine and dolutegravir (DTG) plus either of two...
TAF Based Regimen Superior to TDF–based Regimen in Efficacy and Renal and Bone Safety for Initial HIV-1 Treatment
This was a 144-week analysis comparing the efficacy and safety of TAF vs TDF, each co-formulated with elvitegravir, cobicistat, and emtricitabine (e...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6
